PALO ALTO, Calif., February 18, 2016 – Syapse, the leader in precision medicine software, announced today the creation of the Syapse Global Partner Program (GPP), which will leverage best-of-breed partners to enhance and accelerate the implementation of the Syapse Precision Medicine Platform at healthcare organizations globally.
Under the program, Syapse will build an ecosystem of partners, including system integrators, EHR vendors, testing labs, specialty pharmacies and health plans, to further complement the capabilities of Syapse Precision Medicine Platform. By leveraging Syapse and its global partners, healthcare systems will be able to quickly implement a comprehensive suite of integrated capabilities as they scale their precision medicine programs. The partnership program will also increase the number of trained resources available to implement the Syapse Precision Medicine Platform at a growing number of health systems and cancer care networks, with diverse and expanding needs.
The program will be led by BG Jones, who joins Syapse as Vice President of Global Partner Alliances. Jones brings a wealth of experience in architecting commercial alliances and business development partnerships. Previously, he led Global Partner Alliances and strategic business development at Orion Health. Based in Washington, D.C., he will also expand Syapse’s footprint in federal healthcare agencies and clinical research institutes, as well as in international healthcare systems.
“BG’s experience in bringing together key partners to meet the needs of the precision medicine marketplace is essential as Syapse continues to grow and expand the scope of our platform and its geographic reach.” said Glenn Winokur, Syapse CEO & Co-Founder.
“There is a massive opportunity to accelerate the adoption of precision medicine in the U.S. healthcare marketplace and internationally,” said BG Jones. “By bringing together complementary partners across many clinical disciplines, we have the ability to drive the creation of operational best practices, making the successes of early adopter institutions replicable at other institutions around the globe.”
Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models. Syapse Precision Medicine Platform is a comprehensive software suite used by leading health systems to support the clinical implementation of precision medicine in oncology and other service lines. This category-defining platform enables clinical and genomic data integration, decision support, care coordination, and quality improvement at point of care. Headquartered in Palo Alto, California, with offices in Philadelphia, Pennsylvania, Syapse is backed by Ascension Ventures, Safeguard Scientifics (NYSE:SFE), and Social Capital. For more information, visit www.syapse.com.